You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
|
|---|---|
| Published in |
BMC Cancer, March 2019
|
| DOI | 10.1186/s12885-019-5413-y |
| Pubmed ID | |
| Authors |
Paul Lesueur, Justine Lequesne, Jean-Michel Grellard, Audrey Dugué, Elodie Coquan, Pierre-Emmanuel Brachet, Julien Geffrelot, William Kao, Evelyne Emery, David Hassanein Berro, Laurent Castera, Nicolas Goardon, Joëlle Lacroix, Marie Lange, Aurélie Capel, Alexandra Leconte, Benoit Andre, Angélique Léger, Anaïs Lelaidier, Bénédicte Clarisse, Dinu Stefan |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 118 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 12% |
| Researcher | 13 | 11% |
| Student > Bachelor | 11 | 9% |
| Student > Master | 9 | 8% |
| Unspecified | 8 | 7% |
| Other | 24 | 20% |
| Unknown | 39 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 27% |
| Biochemistry, Genetics and Molecular Biology | 9 | 8% |
| Unspecified | 8 | 7% |
| Neuroscience | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Other | 14 | 12% |
| Unknown | 44 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2019.
All research outputs
#15,035,755
of 23,132,033 outputs
Outputs from BMC Cancer
#3,723
of 8,395 outputs
Outputs of similar age
#210,051
of 353,450 outputs
Outputs of similar age from BMC Cancer
#76
of 173 outputs
Altmetric has tracked 23,132,033 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,395 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,450 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 173 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.